ANNEXON INC. - COMMON STOCK

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

07 Jan 2024 20:00:05 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

20 Dec 2023 17:27:50 By Nasdaq GlobeNewswire

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

20 Dec 2023 17:10:53 By Nasdaq GlobeNewswire

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

20 Dec 2023 17:08:02 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

22 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

13 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

09 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

24 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

10 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

19 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

18 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

07 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

30 Jul 2023 12:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

27 Jul 2023 06:30:00 By Nasdaq GlobeNewswire

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

24 May 2023 16:01:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 May 2023 16:01:00 By Nasdaq GlobeNewswire